Gland Pharma gets USFDA nod for generic injectable
Gland Pharma on Wednesday said it has received approval from the US health regulator to market a generic product used to raise blood pressure.
Gland Pharma on Wednesday said it has received approval from the US health regulator to market a generic product used to raise blood pressure.
The Hyderabad-based company has received tentative approval from the US Food and Drug Administration (USFDA) for Angiotensin II Injection, 2.5 mg/mL Single Dose Vial, it said in a regulatory filing.
The company believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity, it added.
According to IQVIA data, Angiotensin II Injection (2.5 mg/mL Single Dose Vial) has US sales of around USD 38 million for twelve months ended in September 2023.
Shares of drug firm were trading 0.68 per cent down at Rs 1,613.35 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SRH vs GT IPL 2024 Ticket Booking Online: Where and how to buy SRH vs GT tickets online - Check IPL Match 66 ticket price, other details
Top 7 SWP Mutual Funds: Rs 50 lakh investment, Rs 70K monthly pension for 10 years, and Rs 42.30 lakh balance value; know more details
Gold and Silver rate today (May 13, 2024): Precious metal under pressure; yellow metal near Rs 72,400, white metal above Rs 84,600
SIP Returns: How Rs 3,000, 5,000, and Rs 10,000 SIPs can help you build retirement corpus of Rs 1.06 cr, Rs 1.77 cr, and Rs 3.53 cr
03:43 PM IST